Evidence map›Paper›PMID 29874151›Full record

ArticleNanomedicine (London, England)2018

Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.

Xin-Shuai Wang, Li Zhang, Xiaocen Li, De-Jiu Kong, Xiao-Chen Hu, Xue-Zhen Ding, Jun-Qiang Yang, Meng-Qi Zhao, Yixuan He, Kit S Lam and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Progress in research on paclitaxel and tumor immunotherapy.Cellular & molecular biology letters · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Xin-Shuai WangHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan, University of Science & Technology, Luoyang 471003, China.
Li ZhangHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan, University of Science & Technology, Luoyang 471003, China.
Xiaocen LiDepartment of Biochemistry & Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
De-Jiu KongHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan, University of Science & Technology, Luoyang 471003, China.
Xiao-Chen HuHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan, University of Science & Technology, Luoyang 471003, China.
Xue-Zhen DingHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan, University of Science & Technology, Luoyang 471003, China.
Jun-Qiang YangHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan, University of Science & Technology, Luoyang 471003, China.
Meng-Qi ZhaoHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan, University of Science & Technology, Luoyang 471003, China.
Yixuan HeDepartment of Biochemistry & Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
Kit S LamDepartment of Biochemistry & Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
She-Gan GaoHenan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan, University of Science & Technology, Luoyang 471003, China.
Tzu-Yin LinDepartment of Internal Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.
Yuanpei LiDepartment of Biochemistry & Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
Henan University of Science and Technology · CNUniversity of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Stimuli-responsive crosslinked theranostics against advanced prostate cancerR01CA199668 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2015 to 2019
$1.8M
Smart targeting nano-theranostics for image-guided drug delivery to pediatric brain tumorsR01HD086195 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2016 to 2020
$1.6M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA199668NICHD NIH HHS R01 HD086195NIH HHS R01CA199668NIH HHS R01HD086195
6 · The paper itself

Abstract

aimThis study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer. MATERIALS &

methodsWe prepared and characterized PTX- and AZD9291-loaded disulfide cross-linking micelles (DCMs), and evaluate their combination effect and toxicity in vitro and in lung cancer-bearing mice.

resultsDrug-loaded DCMs were relatively small in size, and possessed glutathione-responsive drug release. The combination of PTX-DCMs and AZD92921-DCMs exhibited strong synergistic effects in both cell line and in vivo without additional toxicity. Molecular studies demonstrated the synergistic modification in both IKB-α/NF-κB/Bcl-2 and EGFR/Akt pathways.

conclusionThe combination of DCM-loaded AZD9291 and PTX could potentially offer more effective and less toxicity treatment options for lung cancer patients.

Indexed as

Drug Delivery SystemsAcrylamidesAniline CompoundsAnimalsApoptosisCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationDrug LiberationDrug Resistance, NeoplasmHumansIndolesMicePaclitaxelPyrimidinesXenograft Model Antitumor AssaysAcrylamidesAniline CompoundsIndolesosimertinibPaclitaxelPyrimidinesAZD9291EGFR inhibitorNSCLCpaclitaxel

Identifiers

PMID29874151
PMCPMC6219431
OpenAlexW2807695395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.